A facilitated access program to provide Everolimus (RAD) for maintenance for patients completing therapy in RAD trials in solid organ transplantation.

Registry ID
EUCTR2004-001473-25
Source registry
EUCTR
Status
Completed
Phase
PHASE4
Sponsor
Novartis Pharmaceuticals Corporation
Start date
2005-01-27
Completion date
2014-02-14
Last update
2026-08-16

Conditions

Summary

To facilitate the management of patients on maintenance immunosuppression therapy who are completing everolimus trials. To provide everolimus maintenance therapy through this access program and to collect and review safety data until drug is commercially available or the project has been discontinued.

Locations

View on source registry